
Bank of Ireland has been cleared to acquire €9 billion worth of loans from KBC Bank Ireland by the competition watchdog, subject to certain conditions being met. This decision marks another step towards KBC’s exit of the Irish market.
The agreement is subject to a number of binding conditions, including making €1 billion of funding available to non-bank lenders in the Irish mortgage market through the purchasing of securities issued by them. It must also provide €1 million in funding to companies involved in developing innovations relevant to the mortgage markets, and honour certain rates and discounts currently available to KBC customers, as well as offering variable rates equivalent to that of KBC migrated variable rate customers, as well as fixed rate options, to KBC mortgage customers on fixed rates on their first roll-over post-migration.
After carrying out an in-depth assessment of the Bank of Ireland transaction, the Competition and Consumer Protection Commission (CCPC) said the acquisition of the loan portfolio would not substantially lessen competition in Ireland.
Under the deal, Bank of Ireland will acquire almost €9 billion of KBC’s performing loan assets and a small number of non-performing mortgages. It is also taking on €4.4 billion in deposits. However, KBC’s current account customers will have to make alternative banking arrangements.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas